Stella Pharma Corporation (4888.T)
JPY 328.0
(0.31%)
JPY 328.0
(0.31%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 3.82 Billion JPY | -11.74% |
| 2022 | 4.32 Billion JPY | -8.26% |
| 2021 | 4.71 Billion JPY | 130.34% |
| 2020 | 2.04 Billion JPY | -22.99% |
| 2019 | 2.66 Billion JPY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.88 Billion JPY | 27.84% |
| 2023 Q3 | 3.92 Billion JPY | -5.19% |
| 2023 FY | 3.82 Billion JPY | -11.74% |
| 2023 Q2 | 4.14 Billion JPY | -1.31% |
| 2023 Q1 | 4.19 Billion JPY | -3.06% |
| 2023 Q4 | 3.82 Billion JPY | -2.7% |
| 2022 Q2 | 4.35 Billion JPY | 0.0% |
| 2022 Q3 | 4.05 Billion JPY | -6.96% |
| 2022 Q4 | 4.32 Billion JPY | 6.81% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 6.58 Billion JPY | 42.018% |
| PRISM BioLab Co.,LTD | 1.21 Billion JPY | -215.382% |
| GNI Group Ltd. | 62.39 Billion JPY | 93.877% |
| Linical Co., Ltd. | 18.53 Billion JPY | 79.392% |
| Trans Genic Inc. | 9.81 Billion JPY | 61.058% |
| MEDINET Co., Ltd. | 5.63 Billion JPY | 32.188% |
| Soiken Holdings Inc. | 6.94 Billion JPY | 44.996% |
| Cytori Cell Research Institute, Inc. | 5.81 Billion JPY | 34.312% |
| AnGes, Inc. | 28.89 Billion JPY | 86.776% |
| OncoTherapy Science, Inc. | 867.27 Million JPY | -340.532% |
| Nxera Pharma Co., Ltd. | 157.19 Billion JPY | 97.57% |
| Immuno-Biological Laboratories Co., Ltd. | 1.61 Billion JPY | -136.047% |
| NanoCarrier Co., Ltd. | 5.07 Billion JPY | 24.662% |
| Carna Biosciences, Inc. | 4.34 Billion JPY | 12.167% |
| CanBas Co., Ltd. | 2.43 Billion JPY | -57.043% |
| D. Western Therapeutics Institute, Inc. | 2.37 Billion JPY | -60.979% |
| RaQualia Pharma Inc. | 6.93 Billion JPY | 44.871% |
| Chiome Bioscience Inc. | 1.75 Billion JPY | -118.14% |
| Kidswell Bio Corporation | 5.08 Billion JPY | 24.873% |
| PeptiDream Inc. | 67.12 Billion JPY | 94.308% |
| Oncolys BioPharma Inc. | 2.04 Billion JPY | -87.231% |
| Ribomic Inc. | 3.54 Billion JPY | -7.706% |
| SanBio Company Limited | 5.04 Billion JPY | 24.304% |
| Healios K.K. | 15.15 Billion JPY | 74.79% |
| BrightPath Biotherapeutics Co., Ltd. | 1.23 Billion JPY | -210.555% |
| Kubota Pharmaceutical Holdings Co., Ltd. | 3.01 Billion JPY | -26.678% |
| Delta-Fly Pharma, Inc. | 1.47 Billion JPY | -159.174% |
| StemRIM | 9.08 Billion JPY | 57.923% |
| CellSource Co., Ltd. | 6.87 Billion JPY | 44.466% |
| FunPep Company Limited | 2.49 Billion JPY | -53.369% |
| Kringle Pharma, Inc. | 2.61 Billion JPY | -45.9% |
| TMS Co., Ltd. | 3.55 Billion JPY | -7.479% |
| Noile-Immune Biotech Inc. | 5.77 Billion JPY | 33.887% |
| Cuorips Inc. | 6.18 Billion JPY | 38.225% |
| K Pharma,Inc. | 3.31 Billion JPY | -15.291% |
| Takara Bio Inc. | 123.2 Billion JPY | 96.899% |
| ReproCELL Incorporated | 9.05 Billion JPY | 57.795% |
| PhoenixBio Co., Ltd. | 2.71 Billion JPY | -40.706% |
| StemCell Institute Inc. | 6.54 Billion JPY | 41.608% |
| Japan Tissue Engineering Co., Ltd. | 6.98 Billion JPY | 45.332% |
| CellSeed Inc. | 2.46 Billion JPY | -54.947% |